公开(公告)号：US08809369B2

公开(公告)日：2014-08-19

申请号：US13353351

申请日：2012-01-19

Applicant: Lichun Feng ,  Mengwei Huang ,  Yongfu Liu ,  Guolong Wu ,  Shixiang Yan ,  Hongying Yun ,  Mingwei Zhou

Inventor： Lichun Feng ,  Mengwei Huang ,  Yongfu Liu ,  Guolong Wu ,  Shixiang Yan ,  Hongying Yun ,  Mingwei Zhou

IPC: C07D215/48 ,  C07D401/04 ,  C07D401/10 ,  C07D413/10 ,  C07D471/04 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/5377 ,  A61P3/04 ,  A61P3/10

CPC classification number: C07D215/48 ,  C07D401/04 ,  C07D401/10 ,  C07D413/10 ,  C07D471/04

Abstract: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein R1 to R8, A1 to A3 have the are as described herein and compositions including the compounds.

Abstract translation: 本发明涉及式（I）化合物或其药学上可接受的盐或酯，其中R1至R8，A1至A3具有本文所述的化合物和包含该化合物的组合物。

公开(公告)号：US08592594B2

公开(公告)日：2013-11-26

申请号：US13169097

申请日：2011-06-27

Applicant: Li Chen ,  Lichun Feng ,  Yun He ,  Mengwei Huang ,  Yongfu Liu ,  Hongying Yun ,  Mingwei Zhou

Inventor： Li Chen ,  Lichun Feng ,  Yun He ,  Mengwei Huang ,  Yongfu Liu ,  Hongying Yun ,  Mingwei Zhou

IPC: C07D215/38

CPC classification number: C07D215/48 ,  C07D401/06 ,  C07D405/12 ,  C07D471/04

Abstract: A compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein A1 to A3 and R1 to R10 have the significance given in claim 1, can be used as a medicament. These compounds are useful in the treatment or prophylaxis of diseases that are related to AMPK regulation, such as obesity, dyslipidemia, hyperglycemia, type 1 or type 2 diabetes and cancers.

Abstract translation: 式（I）化合物或其药学上可接受的盐或酯，其中A1至A3和R1至R10具有权利要求1中给出的含义，可用作药物。 这些化合物可用于治疗或预防与AMPK调节相关的疾病，例如肥胖症，血脂异常，高血糖症，1型或2型糖尿病和癌症。

公开(公告)号：US20120004218A1

公开(公告)日：2012-01-05

申请号：US13169097

申请日：2011-06-27

Applicant: Li Chen ,  Lichun Feng ,  Yun He ,  Mengwei Huang ,  Yongfu Liu ,  Hongying Yun ,  Mingwei Zhou

Inventor： Li Chen ,  Lichun Feng ,  Yun He ,  Mengwei Huang ,  Yongfu Liu ,  Hongying Yun ,  Mingwei Zhou

IPC: A61K31/541 ,  C07D215/48 ,  C07D413/10 ,  C07D401/10 ,  C07D471/04 ,  C07D405/10 ,  C07D417/14 ,  A61K31/4747 ,  A61K31/47 ,  A61K31/5377 ,  A61K31/496 ,  A61K31/4375 ,  A61P3/04 ,  A61P3/10 ,  A61P35/00 ,  A61P3/06 ,  C07D221/20

CPC classification number: C07D215/48 ,  C07D401/06 ,  C07D405/12 ,  C07D471/04

Abstract: A compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein A1 to A3 and R1 to R10 have the significance given in claim 1, can be used as a medicament. These compounds are useful in the treatment or prophylaxis of diseases that are related to AMPK regulation, such as obesity, dyslipidemia, hyperglycemia, type 1 or type 2 diabetes and cancers.

Abstract translation: 式（I）化合物或其药学上可接受的盐或酯，其中A1至A3和R1至R10具有权利要求1中给出的含义，可用作药物。 这些化合物可用于治疗或预防与AMPK调节相关的疾病，例如肥胖症，血脂异常，高血糖症，1型或2型糖尿病和癌症。

公开(公告)号：US20130196974A1

公开(公告)日：2013-08-01

申请号：US13561366

申请日：2012-07-30

Applicant: Li Chen ,  Lichun Feng ,  Song Feng ,  Lu Gao ,  Tao Guo ,  Mengwei Huang ,  Chungen Liang ,  Yongfu Liu ,  Lisha Wang ,  Jason Christopher Wong ,  Jim Zhen Wu ,  Xihan Wu ,  Hongying Yun ,  Xiufang Zheng

Inventor： Li Chen ,  Lichun Feng ,  Song Feng ,  Lu Gao ,  Tao Guo ,  Mengwei Huang ,  Chungen Liang ,  Yongfu Liu ,  Lisha Wang ,  Jason Christopher Wong ,  Jim Zhen Wu ,  Xihan Wu ,  Hongying Yun ,  Xiufang Zheng

IPC: C07D493/10 ,  C07D487/04 ,  C07D413/04 ,  C07D407/14 ,  C07D401/04 ,  C07D417/14 ,  C07D417/04

CPC classification number: C07D493/10 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D407/14 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D487/04 ,  C07D491/107

Abstract: A compound of formula (I) as well as pharmaceutically acceptable salt thereof, wherein R1 to R10, A, Q, X and Y are as defined in the specification and claims, and their use as a pharmaceutical for the treatment or prophylaxis of respiratory syncytial virus disease.

Abstract translation: 式（I）化合物及其药学上可接受的盐，其中R 1至R 10，A，Q，X和Y如说明书和权利要求中所定义，及其作为治疗或预防呼吸道合胞体药物的用途 病毒病。

公开(公告)号：US08188090B2

公开(公告)日：2012-05-29

申请号：US12614497

申请日：2009-11-09

Applicant: Fariborz Firooznia ,  Tai-An Lin ,  Sung-Sau So ,  Baoxia Wang ,  HongYing Yun

Inventor： Fariborz Firooznia ,  Tai-An Lin ,  Sung-Sau So ,  Baoxia Wang ,  HongYing Yun

IPC: A61K31/445 ,  A61K31/4965 ,  A01N43/40 ,  C07D241/04 ,  C07D295/00 ,  C07D205/00

CPC classification number: C07D295/192 ,  C07D213/74 ,  C07D239/42 ,  C07D295/18 ,  C07D401/12 ,  C07D487/10

Abstract: The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein X, Q and R1-R3 are defined in the detailed description and claims. The invention is also concerned with the compounds of formula Z: and pharmaceutically acceptable salts and esters thereof, wherein R1-R3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I and Z as well as pharmaceutical compositions containing such compounds. The compounds of formula I and Z are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

Abstract translation: 本发明涉及式I化合物及其药学上可接受的盐和酯，其中X，Q和R 1 -R 3在详细描述和权利要求书中定义。 本发明还涉及式Z化合物及其药学上可接受的盐和酯，其中R1-R3在详细描述和权利要求书中定义。 此外，本发明涉及制备和使用式I和Z化合物的方法以及含有这些化合物的药物组合物。 式I和Z的化合物是CRTH2受体的拮抗剂或部分激动剂，可用于治疗与该受体相关的疾病和病症如哮喘。

公开(公告)号：US08871756B2

公开(公告)日：2014-10-28

申请号：US13561366

申请日：2012-07-30

Applicant: Li Chen ,  Lichun Feng ,  Song Feng ,  Lu Gao ,  Tao Guo ,  Mengwei Huang ,  Chungen Liang ,  Yongfu Liu ,  Lisha Wang ,  Jason Christopher Wong ,  Jim Zhen Wu ,  Xihan Wu ,  Hongying Yun ,  Xiufang Zheng

Inventor： Li Chen ,  Lichun Feng ,  Song Feng ,  Lu Gao ,  Tao Guo ,  Mengwei Huang ,  Chungen Liang ,  Yongfu Liu ,  Lisha Wang ,  Jason Christopher Wong ,  Jim Zhen Wu ,  Xihan Wu ,  Hongying Yun ,  Xiufang Zheng

IPC: C07D493/10 ,  C07D487/04 ,  C07D413/04 ,  C07D407/14 ,  C07D401/04 ,  C07D417/14 ,  C07D417/04 ,  C07D409/14 ,  C07D491/107 ,  C07D413/14 ,  C07D405/14 ,  C07D401/14

CPC classification number: C07D493/10 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D407/14 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D487/04 ,  C07D491/107

Abstract: A compound of formula (I) as well as pharmaceutically acceptable salt thereof, wherein R1 to R10, A, Q, X and Y are as defined in the specification and claims, and their use as a pharmaceutical for the treatment or prophylaxis of respiratory syncytial virus disease.

Abstract translation: 式（I）化合物及其药学上可接受的盐，其中R 1至R 10，A，Q，X和Y如说明书和权利要求中所定义，及其作为治疗或预防呼吸道合胞体药物的用途 病毒病。

公开(公告)号：US08354443B2

公开(公告)日：2013-01-15

申请号：US12959408

申请日：2010-12-03

Applicant: Li Chen ,  Lichun Feng ,  Yun He ,  Mengwei Huang ,  Hongying Yun

Inventor： Li Chen ,  Lichun Feng ,  Yun He ,  Mengwei Huang ,  Hongying Yun

IPC: A61K31/404 ,  C07D209/96

CPC classification number: C07D209/96 ,  C07D209/34 ,  C07D401/06 ,  C07D401/08 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D403/10 ,  C07D403/12 ,  C07D405/06 ,  C07D413/06 ,  C07D413/10 ,  C07D413/12 ,  C07D491/107

Abstract: The present invention relates to a compound of formula (I) as well as pharmaceutically acceptable salt thereof, wherein R1 to R4 have the significance given in claim 1. The compound may be used, for example, for the treatment or prophylaxis of obesity, hyperglycemia, dyslipidemia, and type 1 or type 2 diabetes.

Abstract translation: 本发明涉及式（I）化合物及其药学上可接受的盐，其中R1至R4具有权利要求1中给出的含义。该化合物可用于例如治疗或预防肥胖症，高血糖症 ，血脂异常和1型或2型糖尿病。

公开(公告)号：US08268870B2

公开(公告)日：2012-09-18

申请号：US13324650

申请日：2011-12-13

Applicant: Li Chen ,  Fariborz Firooznia ,  Paul Gillespie ,  Yun He ,  Tai-An Lin ,  Sung-Sau So ,  HongYing Yun

Inventor： Li Chen ,  Fariborz Firooznia ,  Paul Gillespie ,  Yun He ,  Tai-An Lin ,  Sung-Sau So ,  HongYing Yun

IPC: A61K31/4439 ,  C07D401/12

CPC classification number: C07D231/56 ,  C07D401/12

Abstract: The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Q, R1-R3 and n are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

公开(公告)号：US08138208B2

公开(公告)日：2012-03-20

申请号：US12497807

申请日：2009-07-06

Applicant: Li Chen ,  Fariborz Firooznia ,  Paul Gillespie ,  Yun He ,  Tai-An Lin ,  Sung-Sau So ,  HongYing Yun ,  Zhenshan Zhang

Inventor： Li Chen ,  Fariborz Firooznia ,  Paul Gillespie ,  Yun He ,  Tai-An Lin ,  Sung-Sau So ,  HongYing Yun ,  Zhenshan Zhang

IPC: A61K31/4439 ,  A61K31/416 ,  C07D231/54 ,  C07D401/02

CPC classification number: C07D231/56 ,  C07D401/12 ,  C07D413/12

Abstract: The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Q, W, X, R1-R5 and n are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

Abstract translation: 本发明涉及式I化合物及其药学上可接受的盐和酯，其中Q，W，X，R 1 -R 5和n在详细描述和权利要求书中定义。 此外，本发明涉及制备和使用式I化合物的方法以及含有这些化合物的药物组合物。 式I化合物是CRTH2受体的拮抗剂，可用于治疗与该受体相关的疾病和病症如哮喘。

公开(公告)号：US20110144106A1

公开(公告)日：2011-06-16

申请号：US12959408

申请日：2010-12-03

Applicant: Li Chen ,  Lichun Feng ,  Yun He ,  Mengwei Huang ,  Hongying Yun

Inventor： Li Chen ,  Lichun Feng ,  Yun He ,  Mengwei Huang ,  Hongying Yun

IPC: A61K31/5377 ,  C07D209/96 ,  C07D401/08 ,  C07D403/10 ,  C07D413/10 ,  C07D401/14 ,  C07D403/12 ,  C07D401/06 ,  C07D405/06 ,  C07D413/06 ,  C07D403/06 ,  C07D403/04 ,  A61K31/403 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/422

CPC classification number: C07D209/96 ,  C07D209/34 ,  C07D401/06 ,  C07D401/08 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D403/10 ,  C07D403/12 ,  C07D405/06 ,  C07D413/06 ,  C07D413/10 ,  C07D413/12 ,  C07D491/107

Abstract: The present invention relates to a compound of formula (I) as well as pharmaceutically acceptable salt thereof, wherein R1 to R4 have the significance given in claim 1. The compound may be used, for example, for the treatment or prophylaxis of obesity, hyperglycemia, dyslipidemia, and type 1 or type 2 diabetes,

Abstract translation: 本发明涉及式（I）化合物及其药学上可接受的盐，其中R1至R4具有权利要求1中给出的含义。该化合物可用于例如治疗或预防肥胖症，高血糖症 ，血脂异常和1型或2型糖尿病，